NASHVILLE — Aegis Sciences Corporation is launching a key opinion leadership series titled “InPractice: Clinical Insights,” on July 26. The panel will feature health care experts from across the country. This series will consist of timely panel discussions regarding topics affecting the health care industry and the myriad ways in which testing can offer clarity on these issues, including the evolution of the designer drug market, addiction recovery plans, effective utilization of medication monitoring, and more.
The first installation of the series, “Designer Drugs: Facing the Impact. Formulating the Solution,” will focus on the current state of synthetic drugs in the United States, the evolution of the drug market, and the impact of designer drugs for communities and the health care field.
WHAT: Aegis Sciences Corporation panel discussion, “Designer Drugs: Facing the Impact. Formulating the Solution.”
WHEN: Tuesday, July 26, at 10 a.m. PT, 11 a.m. MT, 12 p.m. CT and 1 p.m. ET.
WHERE: This is a virtual panel. Register here.
WHO: Joshua Schrecker, Pharm.D., director of Clinical Affairs at Aegis, will serve as the moderator. The panelists will be:
- Kevin Fischer, M.D., chief medical officer of Columbia River Mental Health Services.
- Amy West, MSN, FNP-C, family nurse practitioner for Penobscot Community Healthcare.
- Alex Krotulski, Ph.D., associate director at The Center for Forensic Science Research & Education.
- Bryce Pardo, Ph.D., associate director, Drug Policy Research Center and Policy Researcher at the RAND Corporation.
Founded in 1990, Aegis Sciences Corporation is a laboratory sciences company based in Nashville, Tenn., that provides science-driven testing and consulting services for clients such as health care providers, pharmaceutical companies, professional and amateur sports organizations, leading college and university athletic programs, Fortune 500 corporations, and government agencies throughout the United States. For more information, please visit http://www.aegislabs.com/.
